Physician profile
Leandro Perez
NPI 1447467949
$11,787.12
in general payments reported to CMS, 2019-2025
33 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,286 · 2020: $3,229 · 2021: $1,746 · 2022: $2,009 · 2023: $365 · 2024: $850 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $7,452.48 | 2019-2022 | |
| Boston Scientific Corporation | $549.62 | 2020-2024 | Watchman Flx, Rotablator Rotational Atherectomy System Console Kit, Synergy |
| Novartis Pharmaceuticals Corporation | $540.09 | 2019-2025 | |
| Cardiovascular Systems INC. | $482.65 | 2019 | |
| Abbott Laboratories | $460.59 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $441.20 | 2019-2024 | Xarelto |
| Angiodynamics, INC. | $166.47 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.47 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.83 | 2020-2025 | Jardiance |
| Philips North America LLC | $128.26 | 2022-2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Alnylam Pharmaceuticals INC. | $124.50 | 2024-2025 | Onpattro |
| Pfizer INC. | $123.37 | 2021-2024 | |
| Medtronic Vascular, INC. | $122.83 | 2019 | |
| Heartflow, INC. | $119.12 | 2024-2025 | |
| Amgen INC. | $117.83 | 2022-2025 | Repatha, Repatha |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $81.15 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Siemens Medical Solutions USA, INC. | $73.36 | 2020 | |
| Merck Sharp & Dohme LLC | $63.22 | 2021-2023 | Verquvo |
| Esperion Therapeutics, INC. | $58.92 | 2024-2025 | Nexletol |
| Terumo Medical Corporation | $42.80 | 2020-2021 | |
| Medtronic, INC. | $42.04 | 2021 | |
| Asahi Intecc USA, INC. | $41.16 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.90 | 2021-2024 | Lifevest |
| Scpharmaceuticals INC. | $39.94 | 2024 | |
| Shockwave Medical, INC | $39.80 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Baxter Healthcare | $39.38 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Atricure, INC. | $29.31 | 2022 | |
| Impulse Dynamics (USA) INC. | $24.93 | 2024 | Optimizer |
| Bard Peripheral Vascular, INC. | $21.43 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.60 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.32 | 2024 | |
| Lilly USA, LLC | $16.55 | 2025 | Zepbound, Mounjaro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandro Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.